论文信息 - Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States - 字舞流文

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

J. O’Shaughnessy | Zheng-Yi Zhou | A. Haiderali | P. Hu | W. Xue | Min Huang | W. Pan | Mitashri Chaudhuri | Nicolas Cappoen | C. Le Bailly De Tilleghem | Peter A Fasching | Chelsey Yang | Weiguang Xue | Chelsey Yang | Zheng-Yi Zhou | Peter Hu | N. Cappoen | Joyce O'Shaughnessy | J. O'Shaughnessy